Adagio Medical Holdings Inc.’s (Nasdaq: ADGM) novel cryoablation system for treating life-threatening heart rhythms achieved 84% freedom from shock in a pivotal U.S. trial, setting the stage for a regulatory submission and intensifying competition with giants like Medtronic Plc and Abbott Laboratories.
"FULCRUM-VT represents a seminal step forward in advancing ventricular tachycardia management by delivering positive, clinically meaningful results from the first large-scale, rigorously executed pivotal trial in patients with both ischemic and non-ischemic structural heart disease," Dr. Atul Verma, Director of Cardiology at McGill University Health Centre, said in a statement. "The results are quite encouraging for the broad use of this technology as a long-term solution for patients suffering from VT."
The six-month data from the 209-patient FULCRUM-VT study, presented at the Heart Rhythm Society 2026 conference, showed Adagio's vCLAS system also achieved 59% freedom from any ventricular tachycardia (VT) recurrence. The trial reported a 2.4% rate of major adverse events and a low 1.9% rate of 30-day hospital readmissions related to VT. The company plans to use the results to seek U.S. Food and Drug Administration premarket approval.
These results position Adagio’s ultra-low temperature cryoablation technology as a formidable new entrant in a complex market. Ventricular arrhythmias contribute to about 300,000 sudden cardiac deaths annually in the U.S. alone. Adagio’s success is notable for its consistent outcomes across different patient types, a challenge for existing treatments. The study demonstrated an 84% freedom from ICD shock for ischemic cardiomyopathy patients and 85% for non-ischemic patients, a key differentiator.
A New Benchmark in a Crowded Field
Adagio's positive data lands just as its larger competitors are making their own strides in the VT space. Medtronic recently announced an FDA breakthrough device designation for its Sphere-9 catheter for treating VT. Early data for Sphere-9 showed a 65% freedom from VT recurrence at six months, slightly higher than Adagio's 59%, though from a smaller feasibility study.
Abbott is also advancing its ablation portfolio with the dual-energy TactiFlex Duo catheter, which can deliver both radiofrequency and pulsed-field ablation (PFA). While its recent data focused on atrial fibrillation, showing 87% freedom from arrhythmia, the dual-energy capability highlights the industry trend toward more versatile and effective ablation tools. Adagio’s FULCRUM-VT results, however, compare favorably to both established radiofrequency benchmarks and emerging PFA data for VT, according to the company. The ability to achieve these outcomes with an endocardial-only approach and without the need for irrigation or nitroglycerin could offer a safer, more streamlined procedure.
This article is for informational purposes only and does not constitute investment advice.
